A PUTATIVE ROLE FOR BONE MORPHOGENETIC PROTEIN ANTAGONIST GREMLIN1 IN HER2 POSITIVE BREAST CANCERS

被引：0
|
作者：
Zabkiewicz, C. [1 ]
Ye, L. [1 ]
Hargest, R. [1 ]
机构：
[1] Cardiff Univ, Cardiff China Med Res Collaborat, Cardiff, S Glam, Wales
来源：
BRITISH JOURNAL OF SURGERY | 2019年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
O17
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [31] Bone metastasis trends in HER-2 positive and ER positive breast cancers
    Ignatoski, K. M. W.
    Wallner, L. P.
    Valentine, M.
    Diehl, K. M.
    Keller, E. T.
    CANCER TREATMENT REVIEWS, 2006, 32 : S39 - S40
  • [32] Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
    Yi Ding
    Chang Gong
    De Huang
    Rui Chen
    Pinpin Sui
    Kevin H. Lin
    Gehao Liang
    Lifeng Yuan
    Handan Xiang
    Junying Chen
    Tao Yin
    Peter B. Alexander
    Qian-Fei Wang
    Er-Wei Song
    Qi-Jing Li
    Kris C. Wood
    Xiao-Fan Wang
    Nature Communications, 9
  • [33] Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
    Ding, Yi
    Gong, Chang
    Huang, De
    Chen, Rui
    Sui, Pinpin
    Lin, Kevin H.
    Liang, Gehao
    Yuan, Lifeng
    Xiang, Handan
    Chen, Junying
    Yin, Tao
    Alexander, Peter B.
    Wang, Qian-Fei
    Song, Er-Wei
    Li, Qi-Jing
    Wood, Kris C.
    Wang, Xiao-Fan
    NATURE COMMUNICATIONS, 2018, 9
  • [34] Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis
    Duffy, Laura
    Henderson, John
    Brown, Max
    Pryzborski, Stefan
    Fullard, Nicola
    Summa, Lena
    Distler, Jorg H. W.
    Stratton, Richard
    O'Reilly, Steven
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [35] Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation
    Wang, Yen-Chao
    Morrison, Gladys
    Gillihan, Ryan
    Guo, Jun
    Ward, Robin M.
    Fu, Xiaoyong
    Botero, Maria F.
    Healy, Nuala A.
    Hilsenbeck, Susan G.
    Phillips, Gail Lewis
    Chamness, Gary C.
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Schiff, Rachel
    BREAST CANCER RESEARCH, 2011, 13 (06)
  • [36] HER2 positive breast cancer: is there a preventive role of cardioprotective drugs?
    Martins De Carvalho, M.
    Pinto, R. A.
    Proenca, T.
    Costa, I.
    Torres, S.
    Resende, C. X.
    Grilo, P. D.
    Amador, A. F.
    Costa, C.
    Calvao, J.
    Sousa, C.
    Paiva, M.
    Macedo, F.
    Marques, C.
    Cabrita, A.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2872 - 2872
  • [37] Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation
    Yen-Chao Wang
    Gladys Morrison
    Ryan Gillihan
    Jun Guo
    Robin M Ward
    Xiaoyong Fu
    Maria F Botero
    Nuala A Healy
    Susan G Hilsenbeck
    Gail Lewis Phillips
    Gary C Chamness
    Mothaffar F Rimawi
    C Kent Osborne
    Rachel Schiff
    Breast Cancer Research, 13
  • [38] Breast Cancer Biomarker Changes and Correlations with HER2 Change in ER Positive, HER2 Negative Breast Cancers Treated with Neoadjuvant Endocrine Therapy
    Huang, Wei
    Tyburski, Haley
    Finkelman, Brian
    Turner, Bradley
    Weiss, Anna
    Dhakal, Ajay
    Skinner, Kristin
    Hicks, David
    Zhang, Huina
    LABORATORY INVESTIGATION, 2024, 104 (03) : S175 - S176
  • [39] Predictors of Response to Trastuzumab Containing Neoadjuvant Chemotherapy in HER2 Positive Breast Cancers
    Li, X.
    Kanbour-Shakir, A.
    Dabbs, D.
    Bhargava, R.
    MODERN PATHOLOGY, 2012, 25 : 49A - 50A
  • [40] Predictors of Response to Trastuzumab Containing Neoadjuvant Chemotherapy in HER2 Positive Breast Cancers
    Li, X.
    Kanbour-Shakir, A.
    Dabbs, D.
    Bhargava, R.
    LABORATORY INVESTIGATION, 2012, 92 : 49A - 50A
12345